Bausch + Lomb's Q1: 11 things to know

Bausch + Lomb released its financial report for the first quarter of 2023.

Here are 11 takeaways from a May 3 news release of the report: 

  • Revenues of $931 million across its vision care, surgical and ophthalmic pharmaceutical segments.

  • General accepted accounting principles net loss attributable to Bausch + Lomb Corp. of $90 million.

  • Adjusted earnings before interest, taxes, depreciation and amortization (non-GAAP) of $141 million.

  • Revenues grew 5 percent and 8 percent on a constant currency basis compared to the first quarter of 2022, driven by growth across all segments.

  • Foreign exchange negatively impacted revenues and adjusted EBITDA (non-GAAP) by $31 million and $14 million, respectively.

  • Acquired AcuFocus, whose IC-8 Apthera intraocular lens was approved by the FDA as the first and only small aperture non-toric extended depth of focus IOL for certain cataract patients who have as much as 1.5 diopters of corneal astigmatism and wish to address presbyopia at the same time.

  • Launched PreserVision AREDS 2 Formula mini-soft gels with OCUSorb in the U.S.

  • Introduced the SeeLuma Fully Digital Surgical Visualization Platform in the U.S. and Western Europe in partnership with Heidelberg Engineering.

  • Launched the StableVisc cohesive ophthalmic viscosurgical device, as well as the TotalVisc Viscoelastic System, in the U.S.

  • Results from the two pivotal Phase 3 trials for NOV032 (perfluorohexyloctane), an investigational treatment with a proposed indication of treating the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction, were published in Ophthalmology and the American Journal of Ophthalmology, respectively.

  • Acquired the rights to market Lumify in 18 additional countries.

Financial outlook for remainder of 2023: 

  • Full-year revenue range of $3.90 billion to $3.95 billion, reflecting anticipated growth of 5 percent to 6 percent on a constant currency basis.

  • Full year adjusted EBITDA (non-GAAP) range of $700 million to $750 million.
    • $760 million at the midpoint of the full-year adjusted EBITDA (non-GAAP) guidance range, adjusted for currency headwinds.

  • Foreign exchange revenue and adjusted EBITDA (non-GAAP) headwinds are expected to be approximately $50 million and $35 million for the full year, respectively.


Read the full report here.

Copyright © 2025 Becker's Healthcare. All Rights Reserved. Privacy Policy. Cookie Policy. Linking and Reprinting Policy.


You can unsubscribe from these communications at any time. For more information, please review our Privacy Policy.
 

Articles We Think You'll Like